BIO-RAD LABORATORIES, INC. — Director's Dealing 2021

Sep 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIO-RAD LABORATORIES, INC. (BIO BIOB)
CIK: 0000012208
Period of Report: 2021-09-01

Reporting Person: Last Andrew J. (EVP, Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-01	Bio-Rad A Common Stock	M	2000	$299.24	Acquired	3281.9181	Direct
2021-09-01	Bio-Rad A Common Stock	S	750	$812.27	Disposed	2531.9181	Direct
2021-09-01	Bio-Rad A Common Stock	S	651	$813.15	Disposed	1880.9181	Direct
2021-09-01	Bio-Rad A Common Stock	S	599	$814.09	Disposed	1281.9181	Direct
2021-09-02	Bio-Rad A Common Stock	M	902	—	Acquired	2183.9181	Direct
2021-09-02	Bio-Rad A Common Stock	F	448	$825.77	Disposed	1735.9181	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-01	Restricted Stock Units	$0	A	2532	Acquired		Bio-Rad A Common Stock (2532)	Direct
2021-09-01	Non-Qualified Stock Option (right to buy)	$814.95	A	2532	Acquired	2031-09-01	Bio-Rad A Common Stock (2532)	Direct
2021-09-01	Non-Qualified Stock Option (right to buy)	$299.24	M	2000	Disposed	2029-04-29	Bio-Rad A Common Stock (2000)	Direct
2021-09-02	Restricted Stock Units	$0	M	902	Disposed		Bio-Rad A Common Stock (902)	Direct

Footnotes

F1: Includes 13.9278 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 06/30/2021.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $811.70 to $812.69, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $812.71 to $813.34, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $814.02 to $814.11, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: Shares of Class A common stock acquired on the vesting of restricted stock units.

F6: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

F7: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.

F8: The stock option vests over four years at 25% per year on the yearly anniversary date of the grant.

F9: The option, representing a right to purchase a total of 5,000 shares, became exercisable in five equal annual installments beginning on April 29, 2020, which was the first anniversary of the date on which the option was granted.

F10: On September 2, 2020, the reporting person was granted 3,610 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.